SCHEMBL31395686

SCHEMBL31395686

O=C(O)c1cc(Br)c2c(c1)OCCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.47
HPGD P15428 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.45
PLK1 P53350 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPK1 P28482 1/20 0.41
STAT3 P40763 1/20 0.40
TSHR P16473 2/20 0.40
PKM P14618 1/20 0.38
MAOB P27338 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TPMT P51580 1/20 0.38
CTNNB1 P35222 1/20 0.37
MAPT P10636 1/20 0.37
SRD5A2 P31213 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25391509 0.86 ALDH1A1 (0.53) TTRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL16742124 0.83 TTR (0.44) TTRHPGDNPSR1MEN1KMT2A
SCHEMBL16742122 0.83 TTR (0.44) TTRHPGDNPSR1MEN1KMT2A
SCHEMBL17113270 0.80 MEN1 (0.52) HPGDNPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL3350012 0.79 PLK1 (0.44) HPGDMEN1KMT2ASMN1; SMN2PLK1
SCHEMBL3959311 0.79 TTR (0.47) TTRMEN1KMT2APLK1ALDH1A1
SCHEMBL3072318 0.79 ALDH1A1 (0.44) NPSR1PLK1ALDH1A1MAPK1STAT3
SCHEMBL16742098 0.77 TTR (0.46) TTRNPSR1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL24819228 0.77 TTR (0.46) TTRNPSR1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL16742183 0.77 TSHR (0.41) HPGDSMN1; SMN2PLK1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739307-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY The General Hospital Corporation (US) 2026-05-13 EP disclosed
WO-2025010291-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY THE GENERAL HOSPITAL CORPORATION (US) 2025-01-09 WO disclosed